Abstract
It is now acknowledged that Alzheimer’s disease (AD) neuropathology starts decades before the onset of clinical symptoms, but it remains unknown whether modifiable lifestyle factors can protect against these incipient AD processes, early, in mid-life. Cognitive reserve can explain cognitive preservation in some older adults despite ageing or dementia symptoms, but it is not known whether it can protect against neurodegeneration in mid-life. We asked whether modifiable lifestyle activities contribute to cognitive reserve in mid-life, and whether it can offset the risk of AD in individuals who are cognitively healthy. Cognition, structural, and functional brain health measures were assessed at baseline and two years follow-up, in a cohort of middle-aged participants (N = 210; 40–59 years). Mid-life activities were measured using the Lifetime of Experiences Questionnaire. We assessed the impact of lifestyle activities and known risk factors for sporadic late-onset AD (i.e., the Cardiovascular Risk Factors Aging and Dementia [CAIDE] score) on measures of cognition and brain health. Multivariable linear regression found that mid-life activities made a unique contribution to cognition, independent of education and occupation. Crucially, mid-life activities moderated the relationship between cognitive ability (verbal and visuospatial functions, and conjunctive short-term memory binding) and brain health. Cognitive ability of people with higher mid-life activities, particularly those with high dementia risk scores, was less dependent on their brain functional architecture. Impaired visuospatial function is one of the earliest cognitive deficits in AD and has previously been associated with increased AD risk in this cohort. Additionally, conjunctive memory functions have been found impaired in the pre-symptomatic stages of AD. These findings suggest that modifiable activities contribute uniquely to cognitive reserve in midlife, and may offset the risk of AD. The modifiability of these activities supports their targeting by public health initiatives aimed at dementia prevention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by the UK Alzheimers Society (grant numbers 178 and 264), the US Alzheimers Association (grant number TriBEKa-17-519007) and philanthropic donations.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The NHS Research Ethics Committee of London Camberwell St Giles gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
